{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T04:24:10Z","timestamp":1793593450757,"version":"4.5.0"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.biopha.2018.10.137","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T18:50:00Z","timestamp":1541530200000},"page":"1196-1205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Ankylosing spondylitis and mesenchymal stromal\/stem cell therapy: a new therapeutic approach"],"prefix":"10.1016","volume":"109","author":[{"given":"Kamal","family":"Abdolmohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh Dadgar","family":"Pakdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamideh","family":"Aghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5244-3127","authenticated-orcid":false,"given":"Sara","family":"Assadiasl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0374-2141","authenticated-orcid":false,"given":"Yousef","family":"Fatahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin Hosseini","family":"Rouzbahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Rezaiemanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1947-5658","authenticated-orcid":false,"given":"Lobat","family":"Tayebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9132-1675","authenticated-orcid":false,"given":"Mohammad Hossein","family":"Nicknam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.biopha.2018.10.137_bib0005","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/ard.2008.091793","article-title":"Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine","volume":"68","author":"Landew\u00e9","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.biopha.2018.10.137_bib0010","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1007\/s00296-011-2186-2","article-title":"Evaluation of the Iranian versions of the bath ankylosing spondylitis disease activity index (BASDAI), the bath ankylosing spondylitis functional index (BASFI) and the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis","volume":"32","author":"Bidad","year":"2012","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.biopha.2018.10.137_bib0015","article-title":"Prevalence and characteristics of uveitis in spondylarthropathies: a systematic literature review","author":"Zeboulon","year":"2007","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.137_bib0020","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.berh.2006.03.010","article-title":"Ankylosing spondylitis and bowel disease","volume":"20","author":"Rudwaleit","year":"2006","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"5","key":"10.1016\/j.biopha.2018.10.137_bib0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jbspin.2015.02.006","article-title":"Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: the DESIR cohort","volume":"82","author":"Dougados","year":"2015","journal-title":"Joint Bone Spine"},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0030","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","article-title":"Global prevalence of ankylosing spondylitis","volume":"53","author":"Dean","year":"2013","journal-title":"Rheumatology."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.137_bib0035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/art.23321","article-title":"Women with ankylosing spondylitis: a review","volume":"59","author":"Lee","year":"2008","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"11","key":"10.1016\/j.biopha.2018.10.137_bib0040","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1136\/ard.2007.083089","article-title":"The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research","volume":"67","author":"Song","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.biopha.2018.10.137_bib0045","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J. Rheumatol."},{"issue":"9","key":"10.1016\/j.biopha.2018.10.137_bib0050","first-page":"1694","article-title":"Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index","volume":"21","author":"Jenkinson","year":"1994","journal-title":". The Journal of Rheumatology."},{"issue":"12","key":"10.1016\/j.biopha.2018.10.137_bib0055","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.biopha.2018.10.137_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2018.01.014","article-title":"The role of gut microbiota and IL-23\/IL-17 pathway in ankylosing spondylitis immunopathogenesis: new insights and updates","author":"Babaie","year":"2018","journal-title":"Immunol. Lett."},{"issue":"5","key":"10.1016\/j.biopha.2018.10.137_bib0065","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1080\/14397595.2016.1259716","article-title":"Ankylosing spondylitis M-CSF-derived macrophages are undergoing unfolded protein response (UPR) and express higher levels of interleukin-23","volume":"27","author":"Rezaiemanesh","year":"2017","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.biopha.2018.10.137_bib0070","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.biopha.2018.01.108","article-title":"Immune cells involved in the pathogenesis of ankylosing spondylitis","volume":"100","author":"Rezaiemanesh","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"9906","key":"10.1016\/j.biopha.2018.10.137_bib0075","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"issue":"9313","key":"10.1016\/j.biopha.2018.10.137_bib0080","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2018.10.137_bib0085","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1172\/JCI39143","article-title":"Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed","volume":"119","author":"Miller","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.biopha.2018.10.137_bib0090","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/rheumatology\/ket407","article-title":"Spondyloarthritis: from unifying concepts to improved treatment","volume":"53","author":"Paramarta","year":"2013","journal-title":"Rheumatology."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.137_bib0095","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2018.10.137_bib0100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/ar592","article-title":"Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-\u03b1 therapy and other novel approaches","volume":"4","author":"Braun","year":"2002","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2018.10.137_bib0105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/scrt337","article-title":"Whole body tracking of superparamagnetic iron oxide nanoparticle-labelled cells\u2013a rheumatoid arthritis mouse model","volume":"4","author":"Markides","year":"2013","journal-title":"Stem Cell Res. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.137_bib0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000369708","article-title":"Mesenchymal stem cells mitigate cirrhosis through BMP7","volume":"35","author":"Li","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"issue":"7","key":"10.1016\/j.biopha.2018.10.137_bib0115","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/qjmed\/hcu033","article-title":"Mesenchymal stem cells, autoimmunity and rheumatoid arthritis","volume":"107","author":"El-Jawhari","year":"2014","journal-title":"QJM: An International Journal of Medicine."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0120","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.biocel.2003.11.001","article-title":"Mesenchymal stem cells: clinical applications and biological characterization","volume":"36","author":"Barry","year":"2004","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1634\/stemcells.2006-0335","article-title":"Concise review: multipotent mesenchymal stromal cells in blood","volume":"25","author":"He","year":"2007","journal-title":"Stem Cells"},{"issue":"8","key":"10.1016\/j.biopha.2018.10.137_bib0130","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00296-017-3741-2","article-title":"Association of HLA-B27 with ankylosing spondylitis and clinical features of the HLA-B27-associated ankylosing spondylitis: a meta-analysis","volume":"37","author":"Lin","year":"2017","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.biopha.2018.10.137_bib0135","article-title":"Ankylosing spondylitis: from cells to genes","volume":"2013","author":"Zambrano-Zaragoza","year":"2013","journal-title":"Int. J. Inflam."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.137_bib0140","first-page":"265","article-title":"Immunopathogenesis of ankylosing spondylitis","volume":"8","author":"Kenna","year":"2013","journal-title":"Int. J. Clin."},{"issue":"7","key":"10.1016\/j.biopha.2018.10.137_bib0145","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/1744666X.2018.1491308","article-title":"Complex role of IL-23R polymorphisms on ankylosing spondylitis: a meta-analysis","volume":"14","author":"Zhong","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0150","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1684\/ecn.2014.0350","article-title":"Determination of IL-23 receptor gene polymorphism in Iranian patients with ankylosing spondylitis","volume":"25","author":"Daryabor","year":"2014","journal-title":"Eur. Cytokine Netw."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0155","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jbspin.2011.06.010","article-title":"The associations between interleukin-1 polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis","volume":"79","author":"W-i","year":"2012","journal-title":"Joint Bone Spine"},{"issue":"10","key":"10.1016\/j.biopha.2018.10.137_bib0160","first-page":"17362","article-title":"Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis","volume":"8","author":"Liu","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1759720X09359728","article-title":"Anti-TNF therapy in ankylosing spondylitis: insights for the clinician","volume":"2","author":"Coates","year":"2010","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"18-19","key":"10.1016\/j.biopha.2018.10.137_bib0170","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.lfs.2013.09.003","article-title":"Peripheral B-cell activation and exhaustion markers in patients with ankylosing spondylitis","volume":"93","author":"Niu","year":"2013","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.137_bib0175","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1089\/dna.2015.3046","article-title":"Defective function of CD24+ CD38+ regulatory B cells in Ankylosing Spondylitis","volume":"35","author":"Chen","year":"2016","journal-title":"DNA Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0180","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3892\/etm.2014.2046","article-title":"T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis","volume":"9","author":"Wang","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.biopha.2018.10.137_bib0185","doi-asserted-by":"crossref","first-page":"37559","DOI":"10.1038\/srep37559","article-title":"Functional defects in CD4+ CD25 high FoxP3+ regulatory cells in ankylosing spondylitis","volume":"6","author":"Guo","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0190","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/rheumatology\/kev245","article-title":"Ankylosing spondylitis patients display altered dendritic cell and T cell populations that implicate pathogenic roles for the IL-23 cytokine axis and intestinal inflammation","volume":"55","author":"Wright","year":"2015","journal-title":"Rheumatology."},{"issue":"7","key":"10.1016\/j.biopha.2018.10.137_bib0195","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/intimm\/dxh270","article-title":"The involvement of NK cells in ankylosing spondylitis","volume":"17","author":"Azuz-Lieberman","year":"2005","journal-title":"Int. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2018.10.137_bib0200","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s10067-016-3287-9","article-title":"Associations between ERAP1 polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis","volume":"35","author":"Lee","year":"2016","journal-title":"Clin. Rheumatol."},{"issue":"8","key":"10.1016\/j.biopha.2018.10.137_bib0205","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/ng.873","article-title":"Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility","volume":"43","author":"Evans","year":"2011","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0210","first-page":"294","article-title":"Association between endoplasmic reticulum aminopeptidase-1 (ERAP-1) and susceptibility to ankylosing spondylitis in Iran","volume":"11","author":"Mahmoudi","year":"2012","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"10.1016\/j.biopha.2018.10.137_bib0215","series-title":"Seminars in Arthritis and Rheumatism Elsevier","article-title":"Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: a systematic review","author":"Lubrano","year":"2015"},{"issue":"9783","key":"10.1016\/j.biopha.2018.10.137_bib0220","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.biopha.2018.10.137_bib0225","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.biopha.2018.10.137_bib0230","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ejim.2011.06.006","article-title":"Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications","volume":"22","author":"El Maghraoui","year":"2011","journal-title":"Eur. J. Intern. Med."},{"issue":"6","key":"10.1016\/j.biopha.2018.10.137_bib0235","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/MOG.0b013e32833e91eb","article-title":"NSAID-induced gastrointestinal and cardiovascular injury","volume":"26","author":"Ng","year":"2010","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0240","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K","article-title":"Efficacy of celecoxib, a cyclooxygenase 2\u2013specific inhibitor, in the treatment of ankylosing spondylitis: a six\u2010week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug","volume":"44","author":"Dougados","year":"2001","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.biopha.2018.10.137_bib0245","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/art.27412","article-title":"Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding","volume":"62","author":"Gonz\u00e1lez","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0250","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/acr.20408","article-title":"Population\u2010based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis","volume":"63","author":"Bremander","year":"2011","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"6","key":"10.1016\/j.biopha.2018.10.137_bib0255","doi-asserted-by":"crossref","first-page":"427","DOI":"10.14740\/jocmr2488w","article-title":"Cardiac Involvement in ankylosing spondylitis","volume":"8","author":"Ozkan","year":"2016","journal-title":"J. Clin. Med. Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.137_bib0260","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3109\/03009742.2013.822097","article-title":"A nationwide population-based retrospective cohort study: increased risk of acute coronary syndrome in patients with ankylosing spondylitis","volume":"43","author":"Chou","year":"2014","journal-title":"Scand. J. Rheumatol."},{"issue":"9","key":"10.1016\/j.biopha.2018.10.137_bib0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001098","article-title":"Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies","volume":"8","author":"McGettigan","year":"2011","journal-title":"PLoS Med."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.137_bib0270","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/14397595.2013.844302","article-title":"Clinical characteristics and medical management of Iranian patients with ankylosing spondylitis","volume":"24","author":"Jamshidi","year":"2014","journal-title":"Mod. Rheumatol."},{"issue":"6","key":"10.1016\/j.biopha.2018.10.137_bib0275","first-page":"9581","article-title":"Effectiveness of methylprednisolone in ankylosing spondylitis patients with acute anterior uveitis","volume":"9","author":"Guo","year":"2016","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"10","key":"10.1016\/j.biopha.2018.10.137_bib0280","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporos. Int."},{"issue":"suppl 3","key":"10.1016\/j.biopha.2018.10.137_bib0285","doi-asserted-by":"crossref","first-page":"iii40","DOI":"10.1136\/ard.61.suppl_3.iii40","article-title":"Conventional treatments for ankylosing spondylitis","volume":"61","author":"Dougados","year":"2002","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.137_bib0290","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.berh.2006.03.003","article-title":"Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy","volume":"20","author":"Akkoc","year":"2006","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.137_bib0295","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0306-3623(96)00419-3","article-title":"The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines","volume":"29","author":"Bondeson","year":"1997","journal-title":"Gen. Pharmacol."},{"issue":"21","key":"10.1016\/j.biopha.2018.10.137_bib0300","doi-asserted-by":"crossref","first-page":"13481","DOI":"10.1073\/pnas.172501499","article-title":"Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics","volume":"99","author":"Rajagopalan","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2018.10.137_bib0305","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.biopha.2018.06.015","article-title":"The effects of DMARDs on the expression and function of P-gp, MRPs, BCRP in the treatment of autoimmune diseases","volume":"105","author":"Y-j","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0310","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ncprheum0157","article-title":"Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis","volume":"2","author":"Henderson","year":"2006","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.biopha.2018.10.137_bib0315","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/675108","article-title":"Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-and its soluble receptors during the course of therapy with etanercept and infliximab","volume":"2014","author":"Schulz","year":"2014","journal-title":"Biomed Res. Int."},{"issue":"18","key":"10.1016\/j.biopha.2018.10.137_bib0320","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor \u03b1","volume":"346","author":"Gorman","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2018.10.137_bib0325","series-title":"F1000prime Reports","first-page":"6","article-title":"Advances in managing ankylosing spondylitis","author":"Daikh","year":"2014"},{"issue":"3","key":"10.1016\/j.biopha.2018.10.137_bib0330","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.rdc.2012.08.010","article-title":"Comorbidities in patients with spondyloarthritis","volume":"38","author":"van der Horst-Bruinsma","year":"2012","journal-title":"Rheumatic Disease Clinics."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0335","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/cei.12670","article-title":"The interleukin (IL)\u201023\/IL\u201017 axis in ankylosing spondylitis: new advances and potentials for treatment","volume":"183","author":"Jethwa","year":"2016","journal-title":"Clin. Exp. Immunol."},{"issue":"25","key":"10.1016\/j.biopha.2018.10.137_bib0340","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007145","article-title":"Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: a meta-analysis","volume":"96","author":"Ma","year":"2017","journal-title":"Medicine."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0345","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jmii.2013.03.005","article-title":"Risk of tuberculosis infection in anti-TNF-\u03b1 biological therapy: from bench to bedside","volume":"47","author":"Xie","year":"2014","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.biopha.2018.10.137_bib0350","doi-asserted-by":"crossref","first-page":"32768","DOI":"10.1038\/srep32768","article-title":"Efficacy and safety of TNF-\u03b1 inhibitors for active ankylosing spondylitis patients: multiple treatment comparisons in a network meta-analysis","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0355","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.3892\/etm.2017.5003","article-title":"Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: a meta\u2011analysis of randomized controlled trials","volume":"14","author":"Xu","year":"2017","journal-title":"Exp. Ther. Med."},{"issue":"4 Suppl 78","key":"10.1016\/j.biopha.2018.10.137_bib0360","first-page":"S43","article-title":"Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease","volume":"31","author":"Baraliakos","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0365","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","article-title":"Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years","volume":"11","author":"van der Heijde","year":"2009","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2018.10.137_bib0370","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/acr.22594","article-title":"Impact of Certolizumab Pegol on patient\u2010reported outcomes in patients with axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/j.biopha.2018.10.137_bib0375","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-eular.311","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","author":"Landew\u00e9","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2018.10.137_bib0380","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis","author":"Pathan","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"26","key":"10.1016\/j.biopha.2018.10.137_bib0385","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0390","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.137_bib0395","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/ar4520","article-title":"Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study","volume":"16","author":"Wang","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.137_bib0400","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/1756-185X.12068","article-title":"Mesenchymal stem cell therapy unable to rescue the vision from advanced Behcet\u2019s disease retinal vasculitis: report of three patients","volume":"16","author":"Davatchi","year":"2013","journal-title":"Int. J. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0405","first-page":"467","article-title":"Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction","volume":"10","author":"Mohamad-Hassani","year":"2007","journal-title":"Arch. Iran. Med."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.137_bib0410","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00011-009-0090-y","article-title":"Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis","volume":"59","author":"Mao","year":"2010","journal-title":"Inflamm. Res."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0415","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3904\/kjim.2013.28.4.387","article-title":"Clinical applications of mesenchymal stem cells","volume":"28","author":"Kim","year":"2013","journal-title":"Korean J. Intern. Med."},{"issue":"4 Suppl 92","key":"10.1016\/j.biopha.2018.10.137_bib0420","first-page":"S58","article-title":"Human mesenchymal stem cells as a tool for joint repair in rheumatoid arthritis","volume":"33","author":"Tanaka","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0425","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1186\/1742-2094-10-106","article-title":"Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury","volume":"10","author":"Zhang","year":"2013","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.biopha.2018.10.137_bib0430","first-page":"1","article-title":"Mesenchymal stem cell therapy for acute and chronic pancreatitis","author":"Kawakubo","year":"2017","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.biopha.2018.10.137_bib0435","series-title":"Stem Cells","first-page":"249","article-title":"Mesenchymal stem cells: isolation, in vitro expansion and characterization","author":"Nardi","year":"2008"},{"issue":"14","key":"10.1016\/j.biopha.2018.10.137_bib0440","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-07-298331","article-title":"Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells","volume":"117","author":"Hu","year":"2011","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0445","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nprot.2008.221","article-title":"A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow","volume":"4","author":"Soleimani","year":"2008","journal-title":"Nat. Protoc."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.137_bib0450","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/sctm.16-0363","article-title":"Mesenchymal stem cell\u2010derived extracellular vesicles as mediators of anti\u2010inflammatory effects: endorsement of macrophage polarization","volume":"6","author":"Lo Sicco","year":"2017","journal-title":"Stem Cells Transl. Med."},{"issue":"11","key":"10.1016\/j.biopha.2018.10.137_bib0455","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1038\/emm.2013.94","article-title":"Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine","volume":"45","author":"Murphy","year":"2013","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.137_bib0460","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/ten.tea.2008.0103","article-title":"MSC frequency correlates with blood vessel density in equine adipose tissue","volume":"15","author":"da Silva Meirelles","year":"2008","journal-title":"Tissue Eng. Part A"},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0465","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.137_bib0470","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/14728222.2013.746954","article-title":"Anti-inflammatory role and immunomodulation of mesenchymal stem cells in systemic joint diseases: potential for treatment","volume":"17","author":"MacFarlane","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0475","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10753-011-9298-4","article-title":"Effects of TGF-\u03b2 and b-FGF on the potential of peripheral blood-borne stem cells and bone marrow-derived stem cells in wound healing in a murine model","volume":"35","author":"Bakhshayesh","year":"2012","journal-title":"Inflammation."},{"issue":"9","key":"10.1016\/j.biopha.2018.10.137_bib0480","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/CIRCRESAHA.117.311925","article-title":"Paracrine-mediated systemic anti-inflammatory activity of intravenously administered mesenchymal stem cells: a transformative strategy for cardiac stem cell therapeutics","volume":"121","author":"Epstein","year":"2017","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0485","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11684-011-0164-4","article-title":"Mesenchymal stem cells hold promise for regenerative medicine","volume":"5","author":"Wang","year":"2011","journal-title":"Front. Med. (Lausanne)"},{"issue":"7","key":"10.1016\/j.biopha.2018.10.137_bib0490","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jcyt.2013.03.012","article-title":"Safety and possible outcome assessment of autologous Schwann cell and bone marrow mesenchymal stromal cell co-transplantation for treatment of patients with chronic spinal cord injury","volume":"15","author":"Yazdani","year":"2013","journal-title":"Cytotherapy."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0495","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12967-014-0260-8","article-title":"A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods","volume":"12","author":"Madrigal","year":"2014","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.137_bib0500","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1179\/102453309X402250","article-title":"Isolation and ex vivo expansion of human umbilical cord blood-derived CD34+ stem cells and their cotransplantation with or without mesenchymal stem cells","volume":"14","author":"Delalat","year":"2009","journal-title":"Hematology."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0505","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-9255-2-8","article-title":"Mesenchymal stem cells avoid allogeneic rejection","volume":"2","author":"Ryan","year":"2005","journal-title":"J. Inflamm."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0510","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/ijms19010080","article-title":"Role of stem cells in pathophysiology and therapy of spondyloarthropathies\u2014new therapeutic possibilities?","volume":"19","author":"Krajewska-W\u0142odarczyk","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2018.10.137_bib0515","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1182\/blood-2007-02-069716","article-title":"Immunomodulatory properties of mesenchymal stromal cells","volume":"110","author":"Nauta","year":"2007","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.biopha.2018.10.137_bib0520","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1161\/CIRCRESAHA.116.303614","article-title":"Use of mesenchymal stem cells for therapy of cardiac disease","volume":"116","author":"Karantalis","year":"2015","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0525","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/cells1041045","article-title":"Regenerative effects of mesenchymal stem cells: contribution of muse cells, a novel pluripotent stem cell type that resides in mesenchymal cells","volume":"1","author":"Wakao","year":"2012","journal-title":"Cells."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0530","first-page":"50","article-title":"Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study","volume":"4","author":"Mohyeddin Bonab","year":"2007","journal-title":"Iran. J. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2018.10.137_bib0535","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/resp.12343","article-title":"A phase 1b study of placenta\u2010derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis","volume":"19","author":"Chambers","year":"2014","journal-title":"Respirology."},{"issue":"6","key":"10.1016\/j.biopha.2018.10.137_bib0540","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2217\/rme.10.72","article-title":"Mesenchymal stem cells for the treatment of neurodegenerative disease","volume":"5","author":"Joyce","year":"2010","journal-title":"Regen. Med."},{"issue":"3-4","key":"10.1016\/j.biopha.2018.10.137_bib0545","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1089\/ten.tea.2014.0269","article-title":"Effects of a ceramic biomaterial on immune modulatory properties and differentiation potential of human mesenchymal stromal cells of different origin","volume":"21","author":"Bassi","year":"2014","journal-title":"Tissue Eng. Part A"},{"issue":"12","key":"10.1016\/j.biopha.2018.10.137_bib0550","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/sctm.17-0134","article-title":"A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection","volume":"6","author":"Shi","year":"2017","journal-title":"Stem Cells Transl. Med."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0555","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2017.03.001","article-title":"Infusion of mesenchymal stromal cells after deceased liver transplantation: a phase I\u2013II, open-label","volume":"67","author":"Detry","year":"2017","journal-title":"clinical study. Journal of hepatology."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.137_bib0560","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12185-013-1399-4","article-title":"Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I\/II study","volume":"98","author":"Muroi","year":"2013","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.137_bib0565","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/stem.1314","article-title":"Fetal membrane cells for treatment of steroid\u2010refractory acute graft\u2010versus\u2010host disease","volume":"31","author":"Ringden","year":"2013","journal-title":"Stem Cells"},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0570","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.12545","article-title":"Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid\u2010refractory, grade III\u2013IV acute graft\u2010versus\u2010host disease","volume":"163","author":"Ball","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2018.10.137_bib0575","first-page":"45","article-title":"Adult human mesenchymal stromal cells and the treatment of graft versus host disease","volume":"7","author":"Herrmann","year":"2014","journal-title":"Stem Cells Cloning Adv. Appl."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0580","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.scr.2013.10.001","article-title":"Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GVHD","volume":"12","author":"Wu","year":"2014","journal-title":"Stem Cell Res."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.137_bib0585","article-title":"Reduced intensity conditioning, combined transplantation of haploidentical hematopoietic stem cells and mesenchymal stem cells in patients with severe aplastic anemia","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.biopha.2018.10.137_bib0590","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00277-013-1831-0","article-title":"Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells with a myeloablative regimen for refractory\/relapsed hematologic malignancy","volume":"92","author":"Wu","year":"2013","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.biopha.2018.10.137_bib0595","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2005.02.001","article-title":"Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients","volume":"11","author":"Lazarus","year":"2005","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.biopha.2018.10.137_bib0600","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/968213","article-title":"Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease\u2014a phase II study","volume":"2012","author":"Kuzmina","year":"2012","journal-title":"Stem Cells Int."},{"issue":"10","key":"10.1016\/j.biopha.2018.10.137_bib0605","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archneurol.2010.248","article-title":"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis","volume":"67","author":"Karussis","year":"2010","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0610","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jneuroim.2010.07.013","article-title":"Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study","volume":"227","author":"Yamout","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"12","key":"10.1016\/j.biopha.2018.10.137_bib0615","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113936","article-title":"Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis","volume":"9","author":"Llufriu","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0620","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cgh.2013.06.021","article-title":"A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn\u2019s disease refractory to biologic therapy","volume":"12","author":"Forbes","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.137_bib0625","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/MIB.0b013e31827f27df","article-title":"Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant Crohn\u2019s disease: a phase 1 study","volume":"19","author":"Mayer","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"issue":"12","key":"10.1016\/j.biopha.2018.10.137_bib0630","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/gut.2010.215152","article-title":"Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn\u2019s disease: results of a phase I study","volume":"59","author":"Duijvestein","year":"2010","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.biopha.2018.10.137_bib0635","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1007\/s10350-005-0052-6","article-title":"A phase I clinical trial of the treatment of Crohn\u2019s fistula by adipose mesenchymal stem cell transplantation","volume":"48","author":"Garc\u00eda-Olmo","year":"2005","journal-title":"Dis. Colon Rectum"},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0640","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11684-011-0116-z","article-title":"Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study","volume":"5","author":"Jiang","year":"2011","journal-title":"Front. Med. (Lausanne)"},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0645","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2010.12.010","article-title":"Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial","volume":"92","author":"Lu","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.137_bib0650","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/0961203309348983","article-title":"Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients","volume":"19","author":"Carrion","year":"2010","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.biopha.2018.10.137_bib0655","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nrrheum.2010.80","article-title":"Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE","volume":"6","author":"Liang","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"issue":"8","key":"10.1016\/j.biopha.2018.10.137_bib0660","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/art.27548","article-title":"Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus","volume":"62","author":"Sun","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.biopha.2018.10.137_bib0665","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/ard.2009.123463","article-title":"Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study","volume":"69","author":"Liang","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.137_bib0670","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1756-185X.2011.01599.x","article-title":"Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients","volume":"14","author":"Davatchi","year":"2011","journal-title":"Int. J. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0675","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13287-017-0593-3","article-title":"Mesenchymal stem cells for treating autoimmune dacryoadenitis","volume":"8","author":"Lu","year":"2017","journal-title":"Stem Cell Res. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2018.10.137_bib0680","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1182\/blood-2003-04-1193","article-title":"Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals","volume":"102","author":"Djouad","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0685","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1756-9966-30-9","article-title":"Stem cells in clinical practice: applications and warnings","volume":"30","author":"Lodi","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.137_bib0690","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13024-017-0227-3","article-title":"Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis","volume":"12","author":"Ciervo","year":"2017","journal-title":"Mol. Neurodegener."},{"issue":"10","key":"10.1016\/j.biopha.2018.10.137_bib0695","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3727\/096368913X667727","article-title":"Effects and safety of allogenic mesenchymal stem cell intravenous infusion in active ankylosing spondylitis patients who failed NSAIDs: a 20-week clinical trial","volume":"23","author":"Wang","year":"2014","journal-title":"Cell Transplant."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.137_bib0700","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.3892\/etm.2017.4687","article-title":"Infusion of umbilical cord mesenchymal stem cells alleviates symptoms of ankylosing spondylitis","volume":"14","author":"Li","year":"2017","journal-title":"Exp. Ther. Med."},{"issue":"10","key":"10.1016\/j.biopha.2018.10.137_bib0705","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.humimm.2015.09.038","article-title":"Role of stem cells in spondyloarthritis: pathogenesis, treatment and complications","volume":"76","author":"Wong","year":"2015","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.biopha.2018.10.137_bib0710","unstructured":"ClinicalTrials.gov. Safety and Efficacy Study of Umbilical Cord\/Placenta-Derived Mesenchymal Stem Cells to Treat Ankylosing Spondylitis. ClinicalTrials.gov Identifier: NCT01420432. Available online: www.clinicaltrials.gov."},{"key":"10.1016\/j.biopha.2018.10.137_bib0715","unstructured":"ClinicalTrials.gov. A Molecule Basic Study of Early Warning of New Pathogenic Risk of Ankylosing Spondylitis. ClinicalTrial.gov Identifier: NCT01709656. Available online: www.clinicaltrials.gov."},{"key":"10.1016\/j.biopha.2018.10.137_bib0720","unstructured":"ClinicalTrials.gov. A Pilot Study of MSCs Infusion and Etanercept to Treat Ankylosing Spondylitis. ClinicalTrial.gov Identifier: NCT02809781. Available online: www.clinicaltrials.gov."},{"key":"10.1016\/j.biopha.2018.10.137_bib0725","unstructured":"Chinese Clinical Trial Registry. Clinical Study of Mesenchymal Stem Cells Transplantation in Ankylosing Spondylitis. Registration Number: ChiCTR-TRC-11001417. Available online: http:\/\/www.chictr.org.cn\/enIndex.aspx."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218356762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218356762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:47:01Z","timestamp":1777877221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218356762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":145,"alternative-id":["S0753332218356762"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.10.137","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ankylosing spondylitis and mesenchymal stromal\/stem cell therapy: a new therapeutic approach","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.10.137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}